Michael Garippa Joins SynCardia as President
Former CEO of TandemHeart to Champion
Sales, Clinical Support, Training and Marketing for World’s Only Approved Total Artificial Heart
TUCSON, Ariz. – July 8, 2010 – SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, announced today that Michael Garippa, the CEO and President of TandemHeart for the last 8 years, has left the company to become SynCardia’s new president. Rodger Ford will continue as SynCardia’s CEO, concentrating on business development, while Mr. Garippa focuses on sales, clinical support, training and marketing.
“Now that the Freedom® portable driver is undergoing an FDA IDE clinical study in the U.S. and has received CE approval for use in Europe, stable Total Artificial Heart patients* are able to wait for a matching donor heart at home,” said Ford. “Michael’s experience will provide the launching pad SynCardia needs to serve more of the world’s top transplant centers and their patients.”
Mr. Garippa was recruited by TandemHeart in 2002 as a turnaround expert and stayed on as CEO and President. He took the company from an R&D firm that had lost an aggregate of $50 million and had no commercial sales to a successful company with over $6 million in net income in the past 24 months. The TandemHeart, which provides short-term extracorporeal circulatory support, is currently being used in more than 125 of the top cardiac centers in the U.S. as recognized by U.S. News & World Report.
“The Total Artificial Heart has no equal,” said Mr. Garippa. “It is the only FDA, Health Canada and CE approved Total Artificial Heart in the world. There is no other approved device that provides biventricular replacement for patients with both sides of their heart failing.
“SynCardia already serves 30 of the top transplant centers in the world, with an additional 22 centers currently undergoing SynCardia certification training. The Freedom portable driver has provided us with the opportunity to train additional transplant centers in the U.S., Europe and Australia/New Zealand.”
Prior to joining TandemHeart, Mr. Garippa served as CEO and President of Gateway HomeCare. In addition, Mr. Garippa was Founder and CEO of Millennium HomeCare and The Prompt Care Companies. His background also includes being National Sales Manager at Omni Medical and Senior Analyst with the NYC Health and Hospitals Corporation. Mr. Garippa has a master’s degree from New York University and a Bachelor of Arts degree from Rutgers University.
*Through the IDE clinical study, stable Total Artificial Heart patients who meet study criteria may have the option to be discharged from the hospital with the Freedom portable driver, to wait for their matching donor heart at home and in their communities.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). More than 400 SynCardia Total Artificial Heart implants have been performed since January 2011. The SynCardia Heart has provided almost 130,000 patient days of support from nearly 1,300 implants. The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 76 years old.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.